Specialist and experienced pricing and market access consultancy
We will develop and implement a successful launch strategy for your product.
We build payer focussed pricing and market access strategies to enable commercial success.
We provide engaging training solutions that ensures your organisation stays ahead of the ever-changing market access landscape.
Unifying our internal strengths and external partnerships helps solve your pricing and market access challenges to drive patient access of your pharmaceutical products.
Clearly and concisely communicate key scientific, economic and commercial messages to enable company employees to effectively communicate the product’s value.
Individual solutions to suit you
We adapt our working style to reflect your needs
We have a wealth of practical knowledge & experience within the pharma industry & HTA bodies
We react quickly and effectively to provide the best support possible
We’re thrilled to announce our participation at ISPOR Europe 2023 in Copenhagen this November. We’ll…
Read moreAIFA reform is a landmark change which propels Italy towards expedited drug approvals and improved a…
Read moreThe MHRA grants conditional approval to Casgevy, the first-ever CRISPR gene-editing therapy for sick…
Read moreGovernment, NHS, and Pharma Industry Unveil Successor to Voluntary Scheme for Branded Medicines Pric…
Read moreWe summarise the World Orphan Drug Congress Europe 2023 including keynote and panel sessions on EU H…
Read moreWebinar: Our experts discuss NICE’s proportionate approach to technology appraisals and the implicat…
Read moreWe’ve updated our 2019 analysis which compares the annual and lifetime treatment costs of the 10 mos…
Read moreThis research aims to understand if just three PICOs are feasible by analysing recent HTA assessment…
Read moreOur research aims to gauge awareness of the new EU HTA process within the pharmaceutical industry in…
Read more